Dana White’s Contender Series Alumni Nabbed with Two-Year Suspension for PEDs

In a shocking turn of events, Ukrainian heavyweight fighter Danylo Voievodkin has been handed a two-year suspension by the Combat Sports Anti-Doping (CSAD) program after testing positive for Meldonium, a substance prohibited at all times under the UFC’s Anti-Doping Policy. This setback comes just weeks after Voievodkin earned a UFC contract offer following a stunning submission victory over Bailey Schoenfelder during Dana White’s Contender Series.

UFC debutant and DWCS contract winner 🇺🇦Danylo Voievodkin has failed a drug test and has been suspended for two years.#UFC #MMA pic.twitter.com/e2faEp9pm6

— The Matchmaker (@MMA__Matchmaker) March 20, 2025

Voievodkin, who is only 24 years old and boasts a 7-0 record in MMA, had yet to make his UFC debut. His impressive performance on the Contender Series had generated significant buzz, with many expecting him to be a formidable addition to the heavyweight division. However, the positive test result from an out-of-competition evaluation on October 17 has put his career on hold until November 10, 2026.

Meldonium, the substance for which Voievodkin tested positive, is classified as a Hormone and Metabolic Modulator. It gained notoriety in 2016 when several high-profile athletes, including tennis star Maria Sharapova, were banned for its use. Despite its initial approval for treating certain medical conditions, Meldonium was banned by the World Anti-Doping Agency (WADA) due to its potential performance-enhancing effects.

The CSAD statement on the matter was clear: “There are no mitigating circumstances in this instance that would justify deviating from the standard 24-month penalty for the use of Meldonium, which is considered a non-specified substance under the UFC’s Anti-Doping Policy.” This strict stance underscores the UFC’s commitment to maintaining a clean and fair competitive environment for all fighters.

The Impact on Voievodkin’s Career and the UFC’s Anti-Doping Efforts

Voievodkin’s suspension highlights the challenges faced by fighters navigating the complex landscape of anti-doping regulations. While he had been on the cusp of entering the UFC, his career is now paused, leaving fans and analysts to wonder what could have been. The suspension also serves as a reminder of the UFC’s rigorous anti-doping program, which aims to protect the integrity of the sport.

The UFC’s anti-doping initiative, led by CSAD, has been instrumental in maintaining a level playing field. The program conducts regular testing, both in and out of competition, to ensure that fighters comply with the rules. The use of substances like Meldonium, even if unintentional, can have serious consequences, as seen in Voievodkin’s case.

For Voievodkin, the next two years will be a period of reflection and preparation. He will have ample time to address any issues related to his positive test and work on his skills outside of competition. However, the suspension also means he will miss out on valuable experience and exposure in the UFC, which could impact his career trajectory upon his return.

The broader implications of this suspension extend beyond Voievodkin’s personal career. It reinforces the UFC’s stance on doping and serves as a deterrent to other fighters who might consider using banned substances. The organization’s commitment to fair competition is unwavering, and this case demonstrates that no fighter is exempt from the rules, regardless of their potential or achievements.

Danylo Voievodkin’s two-year suspension is a significant setback for a promising young fighter. While it delays his entry into the UFC, it also underscores the importance of adhering to anti-doping regulations. As Voievodkin prepares for his eventual return, he will have to navigate the challenges of maintaining his skills and staying motivated during his time away from competition. The UFC, meanwhile, continues to emphasize its commitment to a clean sport, ensuring that fighters compete on an equal footing.